Jesse L Berry1,2, Sona Shah1,2, Fiona Kim1,2, Rima Jubran3, Jonathan W Kim1,2. 1. USC Roski Eye Institute, Los Angeles, California, USA. 2. The Vision Center at Children's Hospital Los Angeles, Los Angeles, California, USA. 3. The Children's Center for Cancer and Blood Diseases, Children's Hospital Los Angeles, Los Angeles, California, USA.
Abstract
BACKGROUND: Intravitreal injection of melphalan (IVM) is safe and effective for the treatment of seeding in retinoblastoma. Current protocols require weekly injections during examination under anesthesia (EUA). To avoid additional anesthesia exposure for these children, IVM was initiated at the EUA concurrent with the 4th cycle of systemic chemoreduction in a series of 6 patients with persistent seeding. METHODS: A retrospective review was completed to assess treatment response compared to all patients at our center treated with IVM and systemic chemotherapy. Overall, 6 eyes of 6 patients were included; salvage therapy included systemic chemoreduction with vincristine, etoposide, and carboplatin and IVM for persistent seeding. RESULTS: IVM was initiated in all eyes at cycle 4 of their chemotherapy. Success in eradicating vitreous seeds was 100%; overall salvage rate was 67%. Anterior toxicity was observed in 2 out of 6 eyes and posterior toxicity in 4 out of 6 eyes. CONCLUSION: The concurrent chemoreduction and IVM protocol demonstrated a similar efficacy of globe salvage while sparing children additional EUAs. However, the increased rates of observed melphalan-related toxicities for concurrent therapy are concerning. Further clinical experience is necessary to define the best initiation time and dosing schedule for IVM.
BACKGROUND: Intravitreal injection of melphalan (IVM) is safe and effective for the treatment of seeding in retinoblastoma. Current protocols require weekly injections during examination under anesthesia (EUA). To avoid additional anesthesia exposure for these children, IVM was initiated at the EUA concurrent with the 4th cycle of systemic chemoreduction in a series of 6 patients with persistent seeding. METHODS: A retrospective review was completed to assess treatment response compared to all patients at our center treated with IVM and systemic chemotherapy. Overall, 6 eyes of 6 patients were included; salvage therapy included systemic chemoreduction with vincristine, etoposide, and carboplatin and IVM for persistent seeding. RESULTS: IVM was initiated in all eyes at cycle 4 of their chemotherapy. Success in eradicating vitreous seeds was 100%; overall salvage rate was 67%. Anterior toxicity was observed in 2 out of 6 eyes and posterior toxicity in 4 out of 6 eyes. CONCLUSION: The concurrent chemoreduction and IVM protocol demonstrated a similar efficacy of globe salvage while sparing children additional EUAs. However, the increased rates of observed melphalan-related toxicities for concurrent therapy are concerning. Further clinical experience is necessary to define the best initiation time and dosing schedule for IVM.
Authors: Carol L Shields; Fairooz P Manjandavida; Sruthi Arepalli; Swathi Kaliki; Sara E Lally; Jerry A Shields Journal: JAMA Ophthalmol Date: 2014-03 Impact factor: 7.389
Authors: Jesse L Berry; Rima Jubran; Jonathan W Kim; Kenneth Wong; Simon R Bababeygy; Hashem Almarzouki; Thomas C Lee; A Linn Murphree Journal: Pediatr Blood Cancer Date: 2012-09-19 Impact factor: 3.167
Authors: Jasmine H Francis; Paula Schaiquevich; Emiliano Buitrago; María José Del Sole; Gustavo Zapata; J Oscar Croxatto; Brian P Marr; Scott E Brodie; Alejandro Berra; Guillermo L Chantada; David H Abramson Journal: Ophthalmology Date: 2014-05-10 Impact factor: 12.079
Authors: Jasmine H Francis; David H Abramson; Y Pierre Gobin; Brian P Marr; Ira J Dunkel; Elyn R Riedel; Scott E Brodie Journal: PLoS One Date: 2014-01-20 Impact factor: 3.240
Authors: Rima F Jubran; Judith G Villablanca; Mark Krailo; Jin Piao; Li Huang; A Linn Murphree; Joan O'Brien; Dan Gombos; Carol L Shields; Anna Meadows; Murali Chintagumpala Journal: Pediatr Blood Cancer Date: 2020-06-26 Impact factor: 3.167
Authors: Carley M Bogan; Janene M Pierce; Stephanie D Doss; Yuankai K Tao; Sheau-Chiann Chen; Kelli L Boyd; Albert Liao; Terry Hsieh; David H Abramson; Jasmine H Francis; Debra L Friedman; Ann Richmond; Anthony B Daniels Journal: Exp Eye Res Date: 2021-01-11 Impact factor: 3.467
Authors: Albert Liao; Terry Hsieh; Jasmine H Francis; Jessica A Lavery; Audrey Mauguen; Scott E Brodie; David H Abramson Journal: Retina Date: 2021-01-01 Impact factor: 3.975
Authors: Jessica V Kaczmarek; Carley M Bogan; Janene M Pierce; Yuankai K Tao; Sheau-Chiann Chen; Qi Liu; Xiao Liu; Kelli L Boyd; M Wade Calcutt; Thomas M Bridges; Craig W Lindsley; Debra L Friedman; Ann Richmond; Anthony B Daniels Journal: Invest Ophthalmol Vis Sci Date: 2021-11-01 Impact factor: 4.799